The US Food and Drug Administration will soon be selecting sponsors to participate in its Support for clinical Trials Advancing Rare disease Therapeutics (START) pilot program, which is intended to speed up the development of novel drug and biological products to treat rare diseases, but competition for the slots may not be as intense as initially anticipated.
Sponsors can submit an amendment to their investigational new drug application requesting to participate in the program from 2 January...







